GOP lawmaker moves to overhaul bill protecting drug discounts critical to some KY hospitals
A Northern Kentucky lawmaker has proposed a new version of a bill meant to protect a program that generates income for charity health care that some Kentucky hospitals say is essential for their survival.
'This is a very critical program for our hospitals and access to care in rural communities,' Nancy Galvagni, president of the Kentucky Hospital Association, told a legislative committee Feb. 5, referring to the federal 340B Drug Pricing Program.
But Sen. Gex Williams, R-Verona, has filed an amendment to Senate Bill 14 to replace it with a measure he said is critical to getting more information about how much money from the program, subsidized by the pharmaceutical industry, is generated and spent before further legislative action.
'It tries to collect some data so we can better understand what we're dealing with,' said Williams, whose legislative page describes him as an engineer and technology consultant. 'The data we collect will enable us to better ascertain the fiscal impact on the state of Kentucky.'
The program, which generates income for charity care from deep discounts drug manufacturers provide hospitals and other entities, such as health clinics, has come under fire from consumer advocates and the pharmaceutical industry for what they say is its rapid growth and lack of oversight.
'When hospitals, other covered entities and their contract pharmacies have free rein to mark up medicines, patients, employers and taxpayers across Kentucky pay the price,' Reid Porter, a spokesman for Pharmaceutical Research and Manufacturers of America, or PhRMA, said in an emailed statement. 'Transparency and accountability are needed to ensure 340B is being used appropriately.'
PhRMA, along with other groups including the Kentucky Association of Manufacturers, oppose SB 14 as filed by Sen. Stephen Meredith, R-Leitchfield and a former hospital CEO.
Meredith did not respond to a request for comment about the changes Williams proposes to SB 14. He has argued his SB14 would preserve an essential income stream especially important to rural hospitals in Kentucky.
At the Feb. 5 meeting of the Senate Health Services Committee he chairs, Meredith said his bill simply mirrors legislation passed in a handful of other states that prevents pharmaceutical companies from restricting drugs sold in Kentucky at discounts of up to 50%. He said some companies have begun imposing such restrictions that limit revenue to Kentucky providers.
'Why should we not be allowed to have this funding when other states do?' asked Meredith, who said it brings in about $122 million a year for Kentucky hospitals, clinics and other entities that serve low-income patients.
The Kentucky Hospital Association, which supports Meredith's bill, agrees.
While Williams' proposal may be 'intended to be helpful,' it doesn't account for how the program generates savings for hospitals by requiring manufacturers to provide them drugs 'at the same price the drug companies charge their best customers,' said Jim Musser, senior vice-president with the association.
'The savings generated from that discounted price allow the hospitals to put the savings toward stretching scarce resources,' he said.
Several supporters of the bill testified the 340B program is especially helpful for expanding access to costly cancer infusion drugs which can cost tens of thousands of dollars.
KY health care providers depend on drug discount program that's facing fire on several fronts
Williams said he hadn't discussed his amendment to SB 14 with Meredith other than to notify him he planned to file it.
'I'm presuming we'll discuss it in caucus,' Williams said, referring to the meeting of the Republican majority that controls the Senate. He said he doesn't know when it might be called on the floor for a vote after committee passage Feb. 5.
Williams' amendment would strip out Meredith's language from SB 14 and replace it with a bill that would require all hospitals and any affiliated facilities, such as health clinics, to file a detailed annual report with the Cabinet for Health and Family Services about how much money they gain from the program and how they use it.
The bill also would apply to 'contract' or outside pharmacies used by those hospitals and clinics which critics say have expanded rapidly to include major drugstore chains and industry middlemen known as pharmacy benefit managers or PBMs.
Williams said the legislature could consider changes to state law after it determines details about how much money the program generates and where it goes.
'I don't know how we can make a decision … without data,' he said.
Williams's proposal does not apply to clinics not affiliated with hospitals such as the state's system of 'safety-net' health clinics authorized by the federal government to provide care for low-income and uninsured patients.
Advocates for the about 30 such clinics across Kentucky had expressed alarm at potential reduction of the funds they say are vital to care they provide.
Molly Lewis, executive director of the Kentucky Primary Care Association, said the 340B program brings in about $19 million a year to the community health clinics, funds she said are essential to caring for patients who can't pay for services.
'We support Senate Bill 14,' she said, referring to Meredith's original bill.
Meanwhile, some advocates continue to seek reforms at the federal level since the federal government oversees the program.
Meredith has said he agrees overall change must come from Congress, which is considering proposals to tighten controls and improve oversight of the 340B program. His bill, he said, is meant to protect Kentucky health providers in the meantime.
'I don't think there's a person involved in health care that realize there need to be some changes, some adjustments to it,' he said at the Feb. 5 hearing. 'But that's not why we're here today.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
3 hours ago
- Forbes
Are The San Antonio Spurs Gearing Up For A Trade This Coming Season?
SAN FRANCISCO, CALIFORNIA - APRIL 09: Interim head coach Mitch Johnson of the San Antonio Spurs ... More looks on against the Golden State Warriors in the first quarter at Chase Center on April 09, 2025 in San Francisco, California. NOTE TO USER: User expressly acknowledges and agrees that, by downloading and or using this photograph, User is consenting to the terms and conditions of the Getty Images License Agreement. (Photo by) The San Antonio Spurs had a very strong draft, selecting Dylan Harper and Carter Bryant, both of whom could become foundational pieces moving forward. In free agency and on the trade market, however, the Spurs made some decisions that now, collectively, seem curious. Spending big on backup centers San Antonio first signed Luke Kornet to a four-year deal worth $41 million, albeit just under $24 million are guaranteed. They then traded for Kelly Olynyk, via the Washington Wizards, and took on his $13.4 million for 2025-2026 on top of it. That's $24.4 million for both of them this season, which is a fair bit of financial cheddar when you consider neither will have a starring role, as both play behind Victor Wembanyama and Jeremy Sochan. Of course, one can argue that Olynyk in particular should be able to play alongside the star Frenchman, but nevertheless, it seems optimistic to expect Olynyk to play an enormous amount of minutes given that he's 34 and played just over 20 minutes per game last season. As such, it's fair to wonder if the Spurs are gearing up to a mid-season trade, if they're in the hunt for a playoff spot. Endless possibilities The Spurs have a plethora of trade assets, both in form of player contracts and draft selections, so it'd make sense if the team is actively looking to make a move near the February trade deadline, especially by using the contracts of Kornet or Olynyk to facilitate a deal. After all, investing over $24 million on backup big men seem at-best optimistic, even if it's only for one year. It thus lends itself to the theory that the Spurs did it to keep their options open. Last trade deadline, San Antonio acquired point guard De'Aaron Fox, and it isn't inconceivable that they're planning on making an acquisition of similar quality, to pair with Fox and Wembanyama. They can easily match salaries for most players, as Keldon Johnson's $17.5 million, and Harrison Barnes' $19 million are also movable, and then align value via draft selections. This isn't to say the Spurs are looking to dramatically accelerate their timeline. The organization have shown patience, even after the selection of Wembanyama, and seem to insist on creating a long-term competitive window, which is the right play. It'll be interesting how to see how they play this over the next 6-12 months. Unless noted otherwise, all stats via PBPStats, Cleaning the Glass or Basketball-Reference. All salary information via Spotrac. All odds courtesy of FanDuel Sportsbook.


New York Post
5 hours ago
- New York Post
Trump's Aug. 1 tariff deadline is set in stone, Lutnik says: ‘No extensions, no more grace periods'
President Trump's 'Liberation Day' tariffs — set to kick in Friday — are set in stone this time and will not be delayed again, Commerce Secretary Howard Lutnick said Sunday. 'No extensions, no more grace periods. Aug. 1, the tariffs are set; they'll go into place. Customs will start collecting the money, and off we go,' Lutnick said on 'Fox News Sunday.' 'Obviously, after Aug. 1, people can still talk to President Trump. I mean, he's always willing to listen, and between now and then, I think the president is going to talk to a lot of people. Whether they can make him happy is another question.' Trump announced a 10% baseline tariff rate on all imports to the US and announced a set of customs rates against virtually every country on the planet during his April 2 'Liberation Day' push. The customized tariff rates were slated to take effect on April 9, but then got delayed 90 days and then postponed again until Aug. 1. 3 Commerce Secretary Howard Lutnick said there won't be a grace period for the Aug. 1 tariff deadline. Fox News 3 President Trump's 'Liberation Day' tariffs are set to kick in on Aug. 1 for countries that didn't cut a deal with him. Getty Images In the time since, Trump has announced preliminary trade deals with the United Kingdom, Vietnam, Japan, Indonesia and the Philippines. Additionally, the Trump administration reached a tariff truce with China and set an Aug. 12 deadline to cut a broader deal. Lutnick stressed that Trump is prioritizing the 'big economies' right now. That includes the European Union. Trump met with European Commission chief Ursula von der Leyen on Sunday during his four-day trip to the United Kingdom. 'We set the table. The team sets the table. But Donald Trump does his negotiations by himself,' he emphasized. The EU is a bloc of 27 countries that, taken together, is one of America's largest sources of trade. Negotiations with the EU have proven to be lengthy and tricky for Trump. Trump has a variety of tariffs in place now, such as a 25% rate on automobiles, aluminum, and steel, as well as 25% on imports from Canada and Mexico that don't comply with the United States-Mexico-Canada Agreement. He's also recently mused about jacking up tariffs on Canada and Mexico. Lutnick touted the revenue gains from those tariffs. 3 President Trump has endeavored to overhaul US trade relations during his second term. AP 'What's going to happen is very few products are actually going to move in price,' he predicted. 'And basically $700 billion, $800 billion, maybe it's possible we get near a trillion dollars of revenue, will come into the United States of America, reducing our deficit.' 'What do you think is paying for no tax on tips, no tax on overtime, no tax on Social Security, right?' he added. 'I think if you take a look at the whole thing, it's going to be fantastic.' Trump has also flexed tariffs in the geopolitical realm. On Saturday, he spoke with the leaders and Cambodia and Thailand, informing them that US trade negotiations will stop unless they cease fighting over a long-contested section of the border. On July 15, the president also threatened Russia with 100% secondary tariffs on Russian oil if it fails to make a deal with neighboring Ukraine. That threat could complicate US trade relations with China and India in particular, which have been taking advantage of cheap Russian oil due to the sanctions on Moscow.

Miami Herald
5 hours ago
- Miami Herald
Legendary Wall Street forecaster Bob Doll is having his best year
Stock market prognosticators are wrong so frequently that observers can rightly wonder if they're making forecasts using the oldest soothsaying methods, drawing pebbles from a pile, dropping hot wax into water, using random dots on paper or, of course, trying to find something magical in numbers. Yet at the start of every year – and again at the midpoint – countless market watchers take their crack at divining the future, mixing educated conjecture, informed hunches and the occasional WAG (wild-ass guess). Related: Veteran analyst drops updated stock market forecast Measured just about any way possible, most of those projections are wrong. CXO Advisory Group analyzed more than 6,500 forecasts-using methodologies ranging from fundamental to technical analysis-made by 68 experts on the U.S. stock market from 2005 through 2012. The investigation found that the accuracy of the forecasts was below 47% on average. That loses to a coin flip. Bloomberg/Getty Images Bad calls tend to be forgotten quickly, as soon as a forecast is updated based on new information. Winning picks are lionized and celebrated, even though the expert may have less staying power than a bull market rally. Wall Streeters sometimes call the tendency to place too much trust in a guru who made the most recent good call the "Elaine Garzarelli Effect." Garzarelli made her reputation as a Lehman Brothers investment strategist by urging clients to get out of the stock market the week before the Black Monday crash in 1987. That call made her one of the most widely quoted strategists on the Street, but it was also the pinnacle of her success. Whether it was brilliant prescience or dumb luck may be argued forever, but she never really duplicated that success. Garzarelli failed to generate much interest when she tried running mutual funds and a call on stocks being 25% undervalued late in 2007 as the global financial crisis was looming, further dimmed her star. While old-timers remember her name – she runs Garzarelli Research and her newsletter suggests that she is currently bullish on small- and mid-caps plus transportation stocks – she is like many one-time stars, known more for one right call than for being right consistently over years or decades. One Wall Street analyst who hasn't shied away from forecasts -- and has a stellar track record -- is Bob Doll, chief executive and investment officer at Crossmark Global Investors. In a 40-plus-year career, Doll has also been the top equity strategist at Blackrock, Nuveen, Merrill Lynch, and Oppenheimer Funds; at each of those stops, Doll-a regular guest on CNBC, Fox Business, and seemingly all financial media outlets-has started each year with 10 forecasts for the coming 12 months. Related: Top analyst sends message on pending ugly earnings miss (plus one big beat) Doll holds his picks up to a grader each year and historically has been right 72% of the time. That's roughly where he stood with his 2024 prognostications. He has said that his best years ever put him at just above 80%. Entering 2025, Doll was expecting "fewer tailwinds, but more tail risks." His picks reflected that, calling for "some bumps in the road, but some good news and probably more volatility," in an interview on Money Life with Chuck Jaffe that aired in January. Now, seven months later, Doll is getting the results he expected. Eight of Doll's 10 picks tend to be tied to the economy and stock market, with one tied to politics and a wildcard. This is what Doll was calling for entering 2025, and how it's turning out: Slower economic growth as unemployment rises past 4.5%. The jury is out on this one, but if unemployment hits Doll's target – it's currently just north of 4% -- mark this as a inflation that stays above Fed's 2% target, causing the central bank to cut rates less than expected. Barring a Fed surprise, this one's on track.10-year Treasury yields primarily between 4% and 5% with wider credit spreads. The 10-year Treasury has spent the year in that range; credit spreads were up around the tariff tantrum but have narrowed since. But if there's an economic slowdown, they will widen and this one will be a fail to achieve the market's consensus 14% expectation entering the year, and yet every sector has up earnings. This forecast is virtually a lock at this point, even with Doll expecting a second-half slowdown that could hurt some volatility rises, with the VIX average approaching 20. The VIX averaged 18.5 in the first quarter and 24.4 in the second, so this call –and the VIX has only been this high in two of the last 13 calendar years – might have seemed like a longshot but now looks like a sure experience a 10% correction and price/earnings ratios contract. The correction went on the books in April, and P/E ratios are down and appear likely to stay that way. This can be marked in the win portfolios beat cap-weighted portfolios and value beats growth. Both of these conditions are true at the moment; the question is whether that will hold up through energy and consumer staples outperform healthcare, technology and industrials. This looked like a sure thing into June, when the margin of outperformance shrank. If financials weaken, it could put this one in jeopardy; barring that, it looks like another win."Congress passes the Trump tax cut extension, reduces regulation, but tariffs and deportation are less than expected." The tariff forecast here is the one thing where Doll looks like he's wrong and won't recover; by year's end, this one is likely to look half-right, making it the one clear blemish that's efforts make progress but fall far short of $2 trillion in annualized savings. Even Doll acknowledges that this was a softball. In a July 22 interview on Money Life with Chuck Jaffe, Doll acknowledged that he now expects to be right at least 70 percent of the time, "but I wish coming into the year we knew which seven we were going to get right. We could make a lot of money. The problem is you don't know which ones you're going to get right and wrong." As for the rest of 2025, Doll gave three quick assessments for where things stand now: "One, the economy is slowing. We just don't know how much it's going to slow. Two, we're beginning to see tariffs show up in the inflation numbers. We don't know how much. And number three we have this tailwind called [artificial intelligence] which is real and is keeping things moving." Further, Doll said he expects the AI play to broaden out. The tailwind called AI has also been particularly strong at the high end of the market. We all were expecting some measure of breadth this year. Are we going to see the breadth show up at some point? Yeah. Well, it obviously occurred in the first quarter, and then it went away in the second quarter. While Doll noted that tariffs seem to be showing up in slight increases in the Consumer Price Index, or CPI, he did not think they would cause a spike in inflation over the rest of the year. "I don't think [the impact of tariffs on inflation] it's going to be horrible," he said. "It's just going to be there. Remember, only 15% approximately of our GDP is from outside the United States. The other 85 is pretty domestic. So it's limited by how much of the economy it really affects. "Now, having said that, remember the Fed saying 'We've got to get inflation down to 2% and they're struggling at 3% and we're not going to get to 2%. And that means all these people who want the Fed to lower rates are going to have to wait a little bit longer." Related: Top analysts say investors are suckers for bad dividend stocks The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.